Criteria of efficacy of adjuvant immunotherapy of surface cancer of the urinary bladder
- Authors: Loran ОВ1, Medvedev VL1, Budnik NV1
-
Affiliations:
- Issue: No 1 (2005)
- Pages: 3-5
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/276321
- ID: 276321
Cite item
Full Text
Abstract
Assessment of prognostic significance of interIeukine-8 (L-8) urine levels was made in 12 patients with verified surface cancer of the urinary bladder (SCUB) on adjuvant intravesical immunotherapy. Quantitative enzyme immunoassay identified IL-8 in the urine before intravesical injection of BCG vaccine and 6 hours later. A total of 192 urine samples were studied ("Multiskan-Jems", 405 nm). Adjuvant immunotherapy raises an L-8 level in the urine of the patients. After 8-week immunotherapy IL-8 elevated from 169.4 pg/ml to 326 pg/ml. Four patients with minimal difference in IL-8 urine levels (120 pg/ml, on the average) before and 6 hours after intravesical injection of BCG vaccine developed recurrence. Thus, quantitative assessment of IL-8 in urine of SCUB patients given intravesical BCG therapy can serve as one of prognostic criteria of adjuvant immunotherapy efficacy.
References
- Лопаткин Н. А. Оперативное лечение опухолей мочевого пузыря. В кн.: Материалы Пленума Всероссийского о-ва урологов. Кемерово; 1995. 157-174.
- Лопаткин Н. А. Руководство по урологии: М.: Медицина; 1998; Т. 1-3.
- Лоран О. Б. Лечение поверхностного рака мочевого пузыря. В кн.: Материалы Всероссийской конф. "Рак мочевого пузыря". Ростов н/Д; 1998. 58-60.
- Матвеев Б. П. Диагностика и лечение рака мочевого пузыря. В кн.: Тезисы материалов VIII Пленума Всесоюзного науч. о-ва урологов. Вильнюс; 1988. 91-100.
- Holmang S., Hedien H., Anderstrom С., Johansson S. L. The relationship among multiple recurrences, progression and prognosis of patients with stages Та and Tl transitional cell cancer of the bladder followed for at least 20 years. J. Urol. (Baltimore) 1995; 153: 1823.
- Пушкарь Д. Ю., Кан Я. Д. Опыт внутрипузырного применения БЦЖ у больных поверхностными формами рака мочевого пузыря. В кн.: Материалы Всероссийской конф. "Рак мочевого пузыря". Ростов н/Д; 1998. 78-79.
- Bohle A., Nowc С., Ulmer A. J. et al. Elevation of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guerin immunotherapy. J. Urol. (Baltimore) 1990; 144: 59.
- De Reijke T. M., de Boer E. C., Kurth К. Н. et al. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value. J. Urol. (Baltimore) 1996; 155: 477.
- Thalmann G. N., Dewald В., Gallati H. et al. Interleukin-4 (IL4). Interleukin-6 (IL-6), Interleukin-8 (IL-8), timor necrosis factor (TNF), tumor necrosis factor receptors (TNFR) 55 and 75 after instillation with Bacillus Calmette-Guerin (BCG) in patients with superficial bladder cancer. J. Urol. (Baltimore) 1993; 149 (suppl.): 337A, abstr. 497.
- Черешнев В. А., Гусев Е. Ю. Иммунология воспаления: роль цитокинов. Мед. иммунол. 2001; 3 (3): 361-368.
- Симбирцев А. С. Интерлейкин-8 и другие хемокины. Иммунология 1999; 4: 9-15.
- Thalmann G. N., Sermier A., Rentsch С. et al. Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmene-Guerin. J. Urol. (Baltimore) 2000; 164: 2129-2133.
Supplementary files
